Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016:2016:1656182.
doi: 10.1155/2016/1656182. Epub 2016 Mar 21.

Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern

Alehegn Gelaye  1 , Abdallah Haidar  2 , Christina Kassab  2 , Syed Kazmi  1 , Prabhat Sinha  1
Affiliations

Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern

Alehegn Gelaye et al. Case Rep Crit Care. 2016.

Abstract

Canagliflozin (Invokana) is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor that was first introduced in 2013 for the treatment of type 2 diabetes mellitus (DM). Though not FDA approved yet, its use in type 1 DM has been justified by the fact that its mechanism of action is independent of insulin secretion or action. However, some serious side effects, including severe anion gap metabolic acidosis and euglycemic diabetic ketoacidosis (DKA), have been reported. Prompt identification of the causal association and initiation of appropriate therapy should be instituted for this life threatening condition.

PubMed Disclaimer

References

    1. US Food and Drug Administration. FDA Drug Safety Communication: FDA Warns That SGLT2 Inhibitors for Diabetes May Result in a Serious Condition of Too Much Acid in the Blood. Bethesda, Md, USA: US Food and Drug Administration; 2015.
    1. Sobieraj D. M. FDA Approves First SGLT2 Inhibitor for T2DM. 2013.
    1. Fala L. Invokana (Canagliflozin): first-in-class SGLT2 inhibitor approved for the treatment of type 2 diabetes. American Health & Drug Benefits. 2014;7 - PMC - PubMed
    1. Scheen A. J. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33–59. doi: 10.1007/s40265-014-0337-y. - DOI - PubMed
    1. Rosenthal N., Meininger G., Ways K., et al. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Annals of the New York Academy of Sciences. 2015 doi: 10.1111/nyas.12852. - DOI - PubMed

LinkOut - more resources